[go: up one dir, main page]

PL2646466T3 - Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie - Google Patents

Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie

Info

Publication number
PL2646466T3
PL2646466T3 PL11791284T PL11791284T PL2646466T3 PL 2646466 T3 PL2646466 T3 PL 2646466T3 PL 11791284 T PL11791284 T PL 11791284T PL 11791284 T PL11791284 T PL 11791284T PL 2646466 T3 PL2646466 T3 PL 2646466T3
Authority
PL
Poland
Prior art keywords
methods
high affinity
producing high
affinity antibodies
antibodies
Prior art date
Application number
PL11791284T
Other languages
English (en)
Inventor
Tim Beaumont
Mark Jeroen Kwakkenbos
Hergen Spits
Adrianus Quirinus Bakker
Koen Wagner
Original Assignee
Aimm Therapeutics B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimm Therapeutics B.V. filed Critical Aimm Therapeutics B.V.
Publication of PL2646466T3 publication Critical patent/PL2646466T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60P—VEHICLES ADAPTED FOR LOAD TRANSPORTATION OR TO TRANSPORT, TO CARRY, OR TO COMPRISE SPECIAL LOADS OR OBJECTS
    • B60P1/00—Vehicles predominantly for transporting loads and modified to facilitate loading, consolidating the load, or unloading
    • B60P1/04—Vehicles predominantly for transporting loads and modified to facilitate loading, consolidating the load, or unloading with a tipping movement of load-transporting element
    • B60P1/28—Tipping body constructions
    • B60P1/283—Elements of tipping devices
    • B60P1/286—Loading buckets
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Transportation (AREA)
  • Mechanical Engineering (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL11791284T 2010-12-02 2011-12-02 Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie PL2646466T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10193562 2010-12-02
US41990910P 2010-12-06 2010-12-06

Publications (1)

Publication Number Publication Date
PL2646466T3 true PL2646466T3 (pl) 2017-09-29

Family

ID=43837992

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11791284T PL2646466T3 (pl) 2010-12-02 2011-12-02 Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie

Country Status (15)

Country Link
US (2) US9206247B2 (pl)
EP (1) EP2646466B1 (pl)
JP (1) JP6013356B2 (pl)
CN (1) CN103429615B (pl)
AU (1) AU2011334867B2 (pl)
BR (1) BR112013013573B1 (pl)
CA (1) CA2819070C (pl)
DK (1) DK2646466T3 (pl)
ES (1) ES2626671T3 (pl)
HU (1) HUE033141T2 (pl)
NZ (1) NZ611600A (pl)
PL (1) PL2646466T3 (pl)
PT (1) PT2646466T (pl)
RU (1) RU2585153C2 (pl)
WO (1) WO2012072814A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
JP5753339B2 (ja) 2005-12-09 2015-07-22 アカデミッシュ メディッシュ セントラム ビーアイジェイ ド ユニバーシテイト バン アムステルダム 抗体産生細胞の安定性に影響を与える手段および方法
ES2666584T3 (es) 2009-07-15 2018-05-07 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
PL2646466T3 (pl) 2010-12-02 2017-09-29 Aimm Therapeutics B.V. Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
WO2015037992A1 (en) * 2013-09-11 2015-03-19 Aimm Therapeutics B.V. Parechovirus specific antibodies
US10825548B2 (en) * 2013-12-02 2020-11-03 Carterra, Inc. Systems and methods of sensing and analyzing antibody blocking interactions
US20170009205A1 (en) 2013-12-23 2017-01-12 Aimm Therapeutics B.V. Ex vivo antibody production
CA2938193C (en) * 2014-01-31 2023-05-02 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
ES2939555T3 (es) * 2014-11-14 2023-04-24 Regeneron Pharma Método para generar anticuerpos de alta afinidad
CN105296436B (zh) * 2015-11-19 2018-06-08 江南大学 一株二叔丁基对甲酚单克隆抗体杂交瘤细胞株及其应用
AU2017367695A1 (en) 2016-12-02 2019-06-13 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
CN111094552B (zh) * 2017-05-08 2023-08-18 清华大学 抗体制备新方法
CA3115149A1 (en) * 2018-10-02 2020-04-09 Immunome, Inc. Antibodies targeting epn1
US12080759B2 (en) * 2021-05-13 2024-09-03 Taiwan Semiconductor Manufacturing Co., Ltd. Transistor source/drain regions and methods of forming the same

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
ATE132190T1 (de) 1988-02-26 1996-01-15 Worcester Found Ex Biology Hemmung von htlv-iii durch exogene oligonukleotide
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
WO1994007367A1 (en) 1992-09-29 1994-04-14 Apollon, Inc. Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
EP0664833B1 (en) 1992-10-05 1996-12-27 HYBRIDON, Inc. Therapeutic anti-hiv oligonucleotide and pharmaceutical
WO1994017086A1 (en) 1993-01-25 1994-08-04 Apollon, Inc. Gene regulation by targeting putative intramolecular triple helix
US5550019A (en) 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
WO1995006409A1 (en) 1993-09-03 1995-03-09 Systemix, Inc. Genetically modified human hematopoietic stem cells and their progeny
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US6001558A (en) 1997-06-25 1999-12-14 Ortho Clinical Diagnostics, Inc. Amplification and detection of HIV-1 and/or HIV 2
EP1214399B1 (en) 1999-09-08 2007-07-11 Genetrol Biotherapeutics High level cytokine production with enhanced cell viability
EP1083230A1 (en) 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Viral replicons and viruses dependent on inducing agents
US7122180B2 (en) 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20050009180A1 (en) 2001-12-10 2005-01-13 Lili Yang Method for the generation of antigen-specific lymphocytes
ATE515189T1 (de) 2001-12-10 2011-07-15 California Inst Of Techn Verfahren zur herstellung von antigenspezifischen lymphozyten
ATE555194T1 (de) 2001-12-18 2012-05-15 Cancer Rec Tech Ltd Methode zur herstellung von proliferierenden und differenzierenden zelllinien
AU2002226390B2 (en) 2001-12-22 2007-11-15 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
JP2005521393A (ja) 2002-03-20 2005-07-21 マサチューセッツ インスティテュート オブ テクノロジー Ｈｉｖ治療
AU2002343870A1 (en) * 2002-11-07 2004-06-07 Kumamoto Technology And Industry Foundation Transgenic mammal carrying ganp and utilization thereof
US20060167230A1 (en) * 2003-01-20 2006-07-27 Takaki Koga Anti-pci neutralizing antibody
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
EP1603949B9 (en) 2003-03-14 2011-02-02 Wyeth LLC Antibodies against human il-21 receptor and uses therefor
PT1694360E (pt) * 2003-11-04 2010-12-13 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos
GB2422845B (en) 2003-11-19 2007-08-01 Us Gov Health & Human Serv Method of inducing memory B cell development and terminal differentiation
GB0327384D0 (en) 2003-11-25 2003-12-31 Queen Mary & Westfield College Gene therapy
US20050238626A1 (en) 2004-04-01 2005-10-27 Lili Yang Antigen specific T cell therapy
WO2005123923A2 (en) 2004-06-17 2005-12-29 Wolfgang Hillen Inducer specific tetracycline repressor proteins and methods of use thereof
EP1627563A1 (en) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
EP1647595A1 (en) 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nucleic acids against viruses, in particular HIV
US7393923B2 (en) 2004-11-08 2008-07-01 The Regents Of The University Of California Red-shifted fluorescent proteins mPlum and mRaspberry and polynucleotides encoding the same
JP5208730B2 (ja) * 2005-05-18 2013-06-12 ノバルティス アーゲー Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法
EP1891209A1 (en) 2005-06-06 2008-02-27 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for generating a t cell against an antigen of interest.
JP4482693B2 (ja) * 2005-08-29 2010-06-16 国立大学法人 岡山大学 抗体産生細胞の特異的選択方法
AU2006316288B2 (en) 2005-11-17 2012-12-20 Tet Systems Gmbh & Co. Kg Inducible expression systems
JP5753339B2 (ja) 2005-12-09 2015-07-22 アカデミッシュ メディッシュ セントラム ビーアイジェイ ド ユニバーシテイト バン アムステルダム 抗体産生細胞の安定性に影響を与える手段および方法
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
CA2678451A1 (en) 2007-02-20 2008-08-28 Robert A. Horlick Somatic hypermutation systems
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2009105150A2 (en) * 2008-01-28 2009-08-27 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
ES2341419B1 (es) 2008-08-14 2011-05-03 Hospital Clinic I Provincial De Barcelona Wnt1 como biomarcador de daño renal.
EP2414507B1 (en) 2009-04-03 2014-07-02 Medical Research Council Mutants of activation-induced cytidine deaminase (aid) and methods of use
ES2666584T3 (es) * 2009-07-15 2018-05-07 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
JP6192294B2 (ja) * 2009-07-15 2017-09-06 エーアイエムエム セラピューティクス ベー．フェー． グラム陽性菌特異的結合化合物
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN102712692B (zh) * 2009-10-06 2014-12-31 医学免疫有限公司 Rsv-特异性结合分子
PL2646466T3 (pl) 2010-12-02 2017-09-29 Aimm Therapeutics B.V. Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie
KR20140112495A (ko) 2011-12-02 2014-09-23 에임 쎄라퓨틱스 비.브이. 인플루엔자 a 바이러스 특이적 항체
US20170009205A1 (en) * 2013-12-23 2017-01-12 Aimm Therapeutics B.V. Ex vivo antibody production

Also Published As

Publication number Publication date
HUE033141T2 (en) 2017-11-28
EP2646466B1 (en) 2017-03-29
BR112013013573A2 (pt) 2016-10-11
US20130331552A1 (en) 2013-12-12
JP2014500726A (ja) 2014-01-16
BR112013013573B1 (pt) 2021-04-27
US9969795B2 (en) 2018-05-15
DK2646466T3 (en) 2017-06-06
PT2646466T (pt) 2017-06-07
JP6013356B2 (ja) 2016-10-25
CN103429615A (zh) 2013-12-04
NZ611600A (en) 2015-02-27
WO2012072814A1 (en) 2012-06-07
RU2013130006A (ru) 2015-01-10
ES2626671T3 (es) 2017-07-25
US9206247B2 (en) 2015-12-08
AU2011334867A1 (en) 2013-06-20
RU2585153C2 (ru) 2016-05-27
CA2819070A1 (en) 2012-06-07
CN103429615B (zh) 2018-03-16
CA2819070C (en) 2020-03-10
AU2011334867B2 (en) 2016-10-13
US20160096881A1 (en) 2016-04-07
EP2646466A1 (en) 2013-10-09

Similar Documents

Publication Publication Date Title
PT2646466T (pt) Meios e métodos para produzir anticorpos de alta afinidade
IL250624B (en) Anti-fgfr3 antibodies and methods of using them
IL240898A0 (en) Antibodies against a5c and methods of using the antibodies
IL223018A0 (en) Method for preparing antibodies having improved properties
EP2534178A4 (en) THERAPEUTIC PROCEDURES WITH TI-CD200 ANTIBODIES
EP2624066A4 (en) LOADING ELEMENT AND METHOD FOR THE MANUFACTURE THEREOF
GB201115529D0 (en) Antibodies, uses and methods
GB201115280D0 (en) Antibodies, uses and methods
IL249501A0 (en) A process for creating antibodies
EP2545104A4 (en) PARTICLES AND METHOD FOR THE PRODUCTION THEREOF
EP2613203A4 (en) LOADING ELEMENT AND PROCESS FOR PRODUCING THE SAME
HK1180345A1 (zh) 篩選抗體的方法
EP2558587A4 (en) METHOD FOR DISPLAYING ANTIBODIES
EP2542706A4 (en) Apparatus and methods for producing direct reduced iron
IL222184A (en) Amino-pyridine-n- oxides are converted and methods of preparation
IL219136A0 (en) Anti-hepsin antibodies and methods using same
HK1158029A1 (en) Cystine-containing complex and method for producing the same
IL266073B (en) Proteins comprising heterodimeric antibody fc and methods for their preparation